XYDALBA

This brand name is authorized in Austria, Estonia, Finland, France, Ireland, Lithuania, Netherlands, Poland, Romania, Spain, UK.

Active ingredients

The drug XYDALBA contains one active pharmaceutical ingredient (API):

1	Dalbavancin UNII 808UI9MS5K - DALBAVANCIN
	Dalbavancin is a bactericidal lipoglycopeptide. Its mechanism of action in susceptible Gram-positive bacteria involves interruption of cell wall synthesis by binding to the terminal D-alanyl-D-alanine of the stem peptide in nascent cell wall peptidoglycan, preventing cross-linking (transpeptidation and transglycosylation) of disaccharide subunits resulting in bacterial cell death.
	Read more about Dalbavancin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
XYDALBA Powder for concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01XA04		J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01X Other antibacterials → J01XA Glycopeptide antibacterials
Discover more medicines within J01XA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1677999
ES	Centro de información online de medicamentos de la AEMPS	114986001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	434329
FR	Base de données publique des médicaments	65987568
GB	Medicines & Healthcare Products Regulatory Agency	343765
LT	Valstybinė vaistų kontrolės tarnyba	1075839
NL	Z-Index G-Standaard, PRK	151580
PL	Rejestru Produktów Leczniczych	100338990
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68939001